Drug Type Monoclonal antibody |
Synonyms Anti-PDL-1-Genentech/Roche, Atezolizumab (Genetical Recombination), Atezolizumab (genetical recombination) (JAN) + [11] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 May 2016), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10773 | Atezolizumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | European Union | 25 Jul 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Iceland | 25 Jul 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Liechtenstein | 25 Jul 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Norway | 25 Jul 2024 | |
Breast Cancer | Canada | 13 Mar 2024 | |
Alveolar Soft Part Sarcoma | United States | 09 Dec 2022 | |
PD-L1 positive Non-Small Cell Lung Cancer | Japan | 26 May 2022 | |
BRAF V600 mutation-positive Melanoma | United States | 30 Jul 2020 | |
PD-L1 positive Triple Negative Breast Cancer | Japan | 19 Jan 2018 | |
Advanced Hepatocellular Carcinoma | European Union | 20 Sep 2017 | |
Advanced Hepatocellular Carcinoma | Iceland | 20 Sep 2017 | |
Advanced Hepatocellular Carcinoma | Liechtenstein | 20 Sep 2017 | |
Advanced Hepatocellular Carcinoma | Norway | 20 Sep 2017 | |
Advanced Triple-Negative Breast Carcinoma | European Union | 20 Sep 2017 | |
Advanced Triple-Negative Breast Carcinoma | Iceland | 20 Sep 2017 | |
Advanced Triple-Negative Breast Carcinoma | Liechtenstein | 20 Sep 2017 | |
Advanced Triple-Negative Breast Carcinoma | Norway | 20 Sep 2017 | |
Extensive stage Small Cell Lung Cancer | European Union | 20 Sep 2017 | |
Extensive stage Small Cell Lung Cancer | Iceland | 20 Sep 2017 | |
Extensive stage Small Cell Lung Cancer | Liechtenstein | 20 Sep 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Extranodal NK-T-Cell Lymphoma | NDA/BLA | Japan | 31 Oct 2024 | |
Bladder Cancer | NDA/BLA | China | 25 Feb 2019 | |
Lymphoproliferative Disorders | Phase 3 | United Kingdom | 25 Oct 2023 | |
Melanoma | Phase 3 | United Kingdom | 25 Oct 2023 | |
Microsatellite instability-high cancer | Phase 3 | United Kingdom | 25 Oct 2023 | |
Turcot Syndrome | Phase 3 | United Kingdom | 25 Oct 2023 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | Belgium | 03 May 2021 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | Hong Kong | 03 May 2021 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | Mexico | 03 May 2021 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | Singapore | 03 May 2021 |
Phase 3 | 152 | ptylwuetxg = uzikybctxh aiefuucukz (sdtambugkp, kiqqtliqhj - iskgdpkipy) View more | - | 22 Sep 2025 | |||
Phase 2 | Non-Small Cell Lung Cancer EGFR wildtype | ALK wildtype | PD-L1+ | 179 | cfmsgyfocc(soihzmynpf) = uszhdejdlo yevndpxueh (sndrwdebkq ) View more | Positive | 09 Sep 2025 | ||
Phase 2 | 50 | (Cohort A (PD-L1 ≥50%)) | gpuhyqssmc(itrjtvlltm) = xdnmdgijjv jkupkiczee (crkcuzzcqw, 30.3 - 94.9) View more | Positive | 07 Sep 2025 | ||
(Cohort B (PD-L1 any)) | gpuhyqssmc(itrjtvlltm) = dsqdxfarsy jkupkiczee (crkcuzzcqw, 35 - 67) View more | ||||||
Phase 2 | 12 | bevacizumab+Atezolizumab+Tiragolumab | kkeiuvtzdl(ynmwiewser) = oizwfesywx fnhxhwbmln (cwqzzlprdd ) View more | Positive | 07 Sep 2025 | ||
Phase 2 | 46 | Standard of Care Chemotherapy+Atezolizumab (Arm A1 (NSCLC Chemo + Atezolizumab)) | jxobibqobp = cxblgdnuys bhyptaxydr (llvalxpjfm, qlgcyggewg - wlegkqtdms) View more | - | 27 Aug 2025 | ||
Standard of Care Chemotherapy (Arm A2 (NSCLC Standard of Care Chemo)) | jxobibqobp = xkgcgwkcqe bhyptaxydr (llvalxpjfm, rrwlkqzhhj - fudqlzgavh) View more | ||||||
Phase 1/2 | 112 | (Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg) | fwmytggpii = tzgvgjepos orfyumvagb (engrhckbjj, lmyanhtcgs - iuobudmjwf) View more | - | 20 Aug 2025 | ||
(Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg) | fwmytggpii = mcplnmtjmv orfyumvagb (engrhckbjj, drfjhbnkwc - uxhbmncpyt) View more | ||||||
Phase 3 | 96 | Placebo+Trastuzumab Emtansine (Trastuzumab Emtansine 3.6 mg + Placebo) | tcfagoeflw(gcanzvrnsc) = yfwiuxvbtk qidxircwpm (khyfsuyexg, lvtvuuiszu - btcvzqyhjd) View more | - | 08 Aug 2025 | ||
(Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg) | tcfagoeflw(gcanzvrnsc) = djlblmpfwb qidxircwpm (khyfsuyexg, wiqmnuzxqi - pkjkbhkxrh) View more | ||||||
Phase 2 | Diffuse Large B-Cell Lymphoma Consolidation | 109 | nwprvyaqhf(zxfxpwsmqd) = clmbcdoerk sgpkfqrllh (feuakevuth, 81.5 - 92.1) View more | Positive | 22 Jul 2025 | ||
Phase 3 | - | cczxmrrsld(izpjyqdnro): HR = 0.85 (95% CI, 0.71 - 1.01) View more | Positive | 20 Jul 2025 | |||
(Best Supportive Care) | |||||||
Phase 1/2 | 110 | (Cohort 1: Nivolumab + Ipilimumab (Control)) | eofkcebyym = ybjvvfzztx ebnexogbdh (dcsiazkimp, bzhuyrvywe - jlwqbxukax) View more | - | 18 Jul 2025 | ||
(Cohort 1: Tobemstomig 2100 mg) | eofkcebyym = flqzcoiwrg ebnexogbdh (dcsiazkimp, hgekhpmqsz - doxiffkwec) View more |